[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation]

Bull Cancer. 2020 Oct;107(10):959-960. doi: 10.1016/j.bulcan.2020.07.007. Epub 2020 Sep 22.
[Article in French]
No abstract available

Keywords: Cancer du sein RH+/HER2; HRpos/HER2neg breast cancer; Inhibiteur de PI3K; Mutation PIK3CA; PI3K inhibitor; PI3K/AKT/mTOR pathway; PIK3CA mutation; Voie PI3K/AKT/mTOR.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms, Male / chemistry
  • Breast Neoplasms, Male / drug therapy
  • Carcinoma, Ductal, Breast / chemistry
  • Carcinoma, Ductal, Breast / drug therapy
  • Carcinoma, Ductal, Breast / secondary*
  • Class I Phosphatidylinositol 3-Kinases / analysis*
  • Class I Phosphatidylinositol 3-Kinases / antagonists & inhibitors
  • Clinical Trials as Topic
  • Drug Approval
  • Drug Resistance, Neoplasm
  • Estrogens*
  • Female
  • Fulvestrant / administration & dosage
  • Humans
  • Male
  • Multicenter Studies as Topic
  • Neoplasm Proteins / analysis*
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasms, Hormone-Dependent / chemistry
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Progesterone*
  • Receptor, ErbB-2 / analysis*
  • Receptors, Estrogen / analysis*
  • Receptors, Progesterone / analysis*
  • Thiazoles / administration & dosage
  • Thiazoles / therapeutic use*

Substances

  • Estrogens
  • Neoplasm Proteins
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Thiazoles
  • Alpelisib
  • Fulvestrant
  • Progesterone
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human
  • ERBB2 protein, human
  • Receptor, ErbB-2